Laura Esserman Journalist Profile

Articles

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).
What is in a Name? Inadvertent Harm from the Designation and Label of 'Cancer' "Presentation" - Laura Esserman

Jul 24, 2024 | urotoday.com | Laura Esserman

Read the Full Video TranscriptLaura Esserman: So what's in a name? There is, of course, inadvertent harm from the designation and the label of cancer. We all know that now cancer is a collection of heterogeneous diseases, which we did not know way back when. Now, Webster's definition is, when you look it up, this is what patients think. It's "A blight, a disease that, left untreated, will kill you." So if it doesn't do that, is that the right term for it? You have to think about that.
No todo lo que denominamos cáncer debe ser llamado así

Sep 26, 2023 | saludconlupa.com | Laura Esserman |Scott Eggener

“Tienes cáncer”. Puedes preguntárselo a cualquiera que le hayan dicho eso: es aterrador. Esa es una de las razones por las que debemos replantearnos lo que llamamos cáncer.
Not everything we call cancer should be called cancer

Sep 5, 2023 | khaleejtimes.com | Laura Esserman |Scott Eggener

Not everything we call cancer should be called cancer Calling something cancer can lead to aggressive treatment even if the cancer in question is unlikely to cause problems.
Not Everything We Call Cancer Should Be Called Cancer

Aug 30, 2023 | nytimes.com | Laura Esserman |Scott Eggener

Laura Esserman and "You have cancer."Ask anyone who has been told this: It's terrifying. That's one reason we need to rethink what we call cancer. Despite amazing advances in our understanding of the disease, we have neglected to update how we define what has been called the emperor of all maladies. Some cancers have extraordinarily low risks of altering the quality or length of life but get lumped in with those that do.
Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply

Jun 14, 2023 | jamanetwork.com | Rita A. Mukhtar |Christina Yau |Laura Esserman

In Reply We thank O’Keefe and Wallace for reading our study.1 In our analysis of data from I-SPY2, a prospective, randomized, neoadjuvant trial with prespecified pathological assessment of specimens according to the Residual Cancer Burden method, we found a nonsignificant difference in 3-year event-free survival (EFS) and distant recurrence-free survival (DRFS) among those with pathologic complete response (pCR) with or without residual ductal carcinoma in situ (DCIS).
Dr. Esserman on the I-SPY2 Trial in Breast Cancer

Mar 3, 2023 | onclive.com | Laura Esserman

Laura J. Esserman, MD, MBA, Alfred A. de Lorimier Endowed Chair in General Surgery, professor, Departments of Surgery and Radiology, affiliate faculty, Institute for Health Policy Studies, University of California San Francisco (UCSF); director, UCSF Breast Care Center; co-leader, Breast Oncology Program, Helen Diller Family Comprehensive Cancer Center, discusses the rationale and design for the phase 2 I-SPY2 trial (NCT01042379).
“Smarter” breast cancer screening measures risk down to your DNA

Feb 16, 2023 | universityofcalifornia.edu | Laura Esserman |Elizabeth Fernandez

While breast cancer deaths have declined in recent years, it remains the second-leading cause of cancer death for women, with more than 40,000 women dying from the disease each year. Women of color have disproportionately higher rates of the most aggressive breast cancers and also higher breast cancer mortality rates. Yet most screening guidelines are the same for everyone: begin annual mammograms at age 40 and continue until 75.